KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Gains from Investment Securities (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Gains from Investment Securities for 3 consecutive years, with $4.3 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Gains from Investment Securities rose 122.02% year-over-year to $4.3 million, compared with a TTM value of -$18.4 million through Dec 2023, down 5070.27%, and an annual FY2024 reading of -$538000.0, down 2439.13% over the prior year.
  • Gains from Investment Securities was $4.3 million for Q4 2023 at Ginkgo Bioworks Holdings, up from -$1.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $19.2 million in Q2 2022 and bottomed at -$19.7 million in Q4 2022.
  • Average Gains from Investment Securities over 3 years is $2.6 million, with a median of $534000.0 recorded in 2021.
  • Peak annual rise in Gains from Investment Securities hit 8462.16% in 2022, while the deepest fall reached 5593.31% in 2022.
  • Year by year, Gains from Investment Securities stood at $359000.0 in 2021, then crashed by 5593.31% to -$19.7 million in 2022, then soared by 122.02% to $4.3 million in 2023.
  • Business Quant data shows Gains from Investment Securities for DNA at $4.3 million in Q4 2023, -$1.9 million in Q3 2023, and $9.9 million in Q2 2023.